HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SangStat Bets on Focus vs. Size

Executive Summary

Up against Novartis, the Swiss marketing giant that now owns the $1.3 billion market for cyclosporine, SangStat insists that its disease management approach to organ transplantation is the right model at the right time.

You may also be interested in...

Facing the Challenges in Transplantation

The transplantation market has changed considerably since Novartis (via its predecessor, Sandoz) launched the then-revolutionary selective immunosuppressant cyclosporin in 1983. Nowadays, clinicians and patients have many more treatment options--thanks largely to enhanced understanding of immunology--and thus the trend is strongly towards individualized therapy. In response to this shift, Novartis has given up pursuing radically new approaches to treatment and is concentrating on developing a product for every class of drug now used to treat graft recipients.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.


Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts